International Aids Vaccine Initiative

Boehringer Ingelheim International Gmbh

Inspirna, Inc.

Ivo Lorenz

Christopher Lee Parks

Sanjay K Phogat

Timothy J Zamb

Keith Allen Canada

Scott Ronald Brodeur

Priyanka Gupta

Masoud Tavazoie

Maoli Yuan

Otmar Schaaf

Haiguang Xiao

Simon Hoffenberg

Christy Jurgens

Aaron J Wilson

Kevin Wright

Xinsheng Zhang

Joseph Robert Woska

Lukasz Chlewicki

Isabel Kurth

Melanie Wurm

Markus Zettl

Svetlana Rabinovich

Arban Domi

Maria J Chiuchiolo

Rocío K Pérez

Celia Andreu-Agullo

Jean-Francois Fortin

C Richter King

Pankaj Gupta

Michael P Caulfield

Fei Han

Abdulsalam Shaaban

Dongmei Liu

Helen Haixia Wu

Shugaku Takeda

Danlin Yang

Walter Carroll Davidson

Nicole K Garaffa

Aaron Timothy Karlak

Joseph A Mozdzierz

David A Blair

Mouhamadou Lamine Mbow

Miguel E Moreno-Garcia

Guangwei Yang

Della M White

Kerry L M Ralph

Joseph Robert Woska Jr

Rocio K Perez

Jean-François Fortin

The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g., human MERTK), and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.

High-affinity anti-MERTK antibodies and uses thereof

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Recombinant viral vectors

The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Antibody molecules for cancer treatment

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

Methods to improve vector expression and genetic stability

The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.

Viral particles derived from an enveloped virus

Growing community of inventors

Brooklyn, NY, United States of America

Ivo Lorenz